These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22927733)

  • 1. Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization.
    Mansour AM; Mackensen F; Mahendradas P; Khairallah M; Lai TY; Bashshur Z
    Clin Ophthalmol; 2012; 6():1233-7. PubMed ID: 22927733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization.
    Mansour AM; Arevalo JF; Fardeau C; Hrisomalos EN; Chan WM; Lai TY; Ziemssen F; Ness T; Sibai AM; Mackensen F; Wolf A; Hrisomalos N; Heiligenhaus A; Spital G; Jo Y; Gomi F; Ikuno Y; Akesbi J; LeHoang P; Adan A; Mahendradas P; Khairallah M; Guthoff R; Ghandour B; Küçükerdönmez C; Kurup SK
    Can J Ophthalmol; 2012 Jun; 47(3):269-74. PubMed ID: 22687305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization.
    Mansour AM; Arevalo JF; Ziemssen F; Mehio-Sibai A; Mackensen F; Adan A; Chan WM; Ness T; Banker AS; Dodwell D; Chau Tran TH; Fardeau C; Lehoang P; Mahendradas P; Berrocal M; Tabbarah Z; Hrisomalos N; Hrisomalos F; Al-Salem K; Guthoff R
    Am J Ophthalmol; 2009 Aug; 148(2):310-316.e2. PubMed ID: 19427992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab in inflammatory ocular neovascularization.
    Mansour AM; Mackensen F; Arevalo JF; Ziemssen F; Mahendradas P; Mehio-Sibai A; Hrisomalos N; Lai TY; Dodwell D; Chan WM; Ness T; Banker AS; Pai SA; Berrocal MH; Tohme R; Heiligenhaus A; Bashshur ZF; Khairallah M; Salem KM; Hrisomalos FN; Wood MH; Heriot W; Adan A; Kumar A; Lim L; Hall A; Becker M
    Am J Ophthalmol; 2008 Sep; 146(3):410-416. PubMed ID: 18619571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: results of a 1-year prospective trial.
    Zhang H; Liu ZL; Sun P; Gu F
    Retina; 2012 Jun; 32(6):1106-13. PubMed ID: 22481479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months.
    Arevalo JF; Adan A; Berrocal MH; Espinoza JV; Maia M; Wu L; Roca JA; Quiroz-Mercado H; Ruiz-Moreno JM; Serrano MA;
    Retina; 2011 Feb; 31(2):353-63. PubMed ID: 20890239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
    Ehrlich R; Ciulla TA; Maturi R; Kheradiya NS; Hrisomalos N; Shulman S; Guess MG; Coyle E; Harris A
    Retina; 2009; 29(10):1418-23. PubMed ID: 19898179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
    Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP
    Retina; 2010; 30(10):1609-15. PubMed ID: 20856171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
    Wakabayashi T; Ikuno Y; Gomi F
    Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
    Smith BT; Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA
    Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis with Active Choroidal Neovascularization Managed with Intravitreal Bevacizumab.
    Chen SN; Chen YL; Yang BC
    Ocul Immunol Inflamm; 2020; 28(1):33-38. PubMed ID: 30994378
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results.
    Julián K; Terrada C; Fardeau C; Cassoux N; Français C; LeHoang P; Bodaghi B
    Acta Ophthalmol; 2011 Mar; 89(2):179-84. PubMed ID: 21348964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of intravitreal bevacizumab and dexamethasone for the treatment of punctate inner choroidopathy associated with choroidal neovascularization: A case series.
    Tsaousis KT; Nassr M; Kapoor B; Konidaris VE; Tyradellis S; Empeslidis T
    SAGE Open Med Case Rep; 2018; 6():2050313X18772478. PubMed ID: 29760922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual and optical coherence tomography outcomes of intravitreal bevacizumab and ranibizumab in inflammatory choroidal neovascularization secondary to punctate inner choroidopathy.
    Cornish KS; Williams GJ; Gavin MP; Imrie FR
    Eur J Ophthalmol; 2011; 21(4):440-5. PubMed ID: 21188681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results.
    Scupola A; Tiberti AC; Sasso P; Savastano MC; Mastrocola A; Marangoni D; Minnella AM; Falsini B; Balestrazzi E
    Retina; 2010 May; 30(5):739-47. PubMed ID: 20038860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Wu TT; Kung YH
    Retina; 2017 Nov; 37(11):2056-2061. PubMed ID: 28590318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
    Chan WM; Lai TY; Liu DT; Lam DS
    Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.